Anti-Microbial Resistance

Home » Anti-Microbial Resistance

Context:

Recently, a strand of antimicrobial-resistant gonorrhea outbreak has hit Kenya.

Relevance:

GS-III: Science and Technology

Dimensions of the Article:

Antimicrobial resistance (AMR) is the ability of microorganisms such as bacteria, fungi, viruses, and parasites to remain unaffected or survive antimicrobial drugs such as antibiotics, antivirals and antimalarials.
AMR occurs when microorganisms exposed to antimicrobial drugs develop antimicrobial resistance resulting in standard treatments becoming ineffective leading to persistence of infections and spreading of infections.
Microorganisms that develop antimicrobial resistance are sometimes referred to as “superbugs”.
The misuse of antimicrobials in medicine and inappropriate use in agriculture is one of the major causes of spread of Antimicrobial Resistance.
Contamination around pharmaceutical manufacturing sites where untreated waste releases large amounts of active antimicrobials into the environment also leads to spread of AMR.

Gonorrhea is a sexually transmitted infection (STI) caused by the bacterium Neisseria gonorrhoeae.
It can affect both men and women in the genitals, rectum, and throat.
If left untreated, it can lead to serious health complications such as infertility and an increased chance of contracting HIV.
It is the second most common sexually transmitted disease worldwide. Gonorrhea is usually treated with antibiotics, however, the bacteria have developed resistance to many of the drugs that were once effective.

Some bacteria due to the presence of resistance genes are intrinsically resistant and therefore survive on being exposed to antibiotics.
Bacteria can also acquire resistance by sharing and transferring resistance genes present in the rest of the population, or by genetic mutations that help the bacteria survive antibiotic exposure.

Multiple drug resistance (MDR), multidrug resistance or multi-resistance is antimicrobial resistance shown by a species of microorganism to multiple antimicrobial drugs.
The types most threatening to public health are MDR bacteria that resist multiple antibiotics; other types include MDR viruses, parasites (resistant to multiple antifungals, antiviral, and antiparasitic drugs of a wide chemical variety).
Recognizing different degrees of MDR, the terms extensively drug resistant (XDR) and pandrug-resistant (PDR) have been introduced.

Medical procedures such as organ transplantation, cancer chemotherapy, diabetes management and major surgery (for example, caesarean sections or hip replacements) become very risky due to AMR.
AMR increases the cost of healthcare with lengthier stays in hospitals, additional tests and use of more expensive drugs.
No new classes of antibiotics have made it to the market in the last three decades, largely on account of inadequate incentives for their development and production.
Without urgent action, we are heading towards a future without antibiotics and with bacteria becoming completely resistant to treatment and when common infections and minor injuries could once again kill (referred to as antibiotic apocalypse).
It is putting the gains of the Millennium Development Goals at risk and endangers achievement of the Sustainable Development Goals.

India, with its combination of large population, rising incomes that facilitate purchase of antibiotics, high burden of infectious diseases and easy over-the-counter access to antibiotics, is an important locus for the generation of resistance genes.
The multi-drug resistance determinant, New Delhi Metallo-beta-lactamase-1 (NDM-1), emerged from this region to spread globally – Africa, Europe and other parts of Asia have also been affected by multi-drug resistant typhoid originating from South Asia.
In India, over 56,000 newborn deaths each year due to sepsis are caused by organisms that are resistant to first line antibiotics.

The use of antibiotics unrelated to treating human disease, such as in food and animal production, must be “optimised”.
Greater action need to be taken to monitor and control infections, globally, nationally and within individual hospitals.
Access to vaccines, clean water and sanitation ought to be expanded.
And finally should be “more thoughtful” about our use of antimicrobial treatments —expanding access to lifesaving antibiotics where needed, minimising use where they are not necessary to improve human health and acting according to WHO’s recommendations on the same.
Increasing funding for developing new antimicrobials and targeting priority pathogens such as K. pneumoniae and E. Coli and ensuring that they are affordable and accessible to most of the world.

-Source: The Hindu